Citations

Clear

2960 citation(s) found for "Kim, In-Ho".

Platelet-derived S100A9 contributes to endotheliopathy in alcohol-associated hepatitis
Kirlin, Fallyn, García-Milian, Rolando , Collin, Florine , Kim, Yohan , Lucien, Fabrice, Sun, Zhaoli, Lam, TuKiet T. , Hwa, John , Iwakiri, Yasuko , McConnell, Matthew J. , Wang, Weiwei , Fattahi, Nima , Wang, Weiwei , Lucien, Fabrice

Mayo Clinic

JCI Insight | August 23, 2026 | Volume: 11 | Issue: 16 | Pages: No page available

10.1172/jci.insight.201114 | PMID 42635042 Get It

Alcohol-associated liver disease (ALD) is a growing global health concern, with alcohol-associated hepatitis (AH) leading to the highest morbidity and mortality. Available therapies are limited and often inadequate. Platelets contribute in a variety of ways to liver disease pathogenesis, but their role in AH remains largely unexplored. In this study, we addressed the hypothesis that platelets contribute to pathological inflammation in AH. Using patient samples and a multiomics approach, we found that platelets undergo proinflammatory transcriptomic and proteomic changes in AH, with 2 alarmins, S100A8 and S100A9, being among the top upregulated genes/proteins. Additionally, the abundance of platelet-derived microparticles containing S100A8 and S100A9 in AH patient plasma was increased and correlated with disease severity (assessed by model for end-stage liver disease sodium [MELD-Na]) and endotheliopathy (assessed by ICAM1, CXCL8, and vWF). We mechanistically linked S100A9 with endotheliopathy via crosstalk between primary human liver sinusoidal endothelial cells and primary human monocytes. We also demonstrated that IL-6 upregulates S100A9 in megakaryocytic cells in a JAK/STAT-dependent manner, modeling changes occurring in the bone marrow in patients with AH. Our studies establish proinflammatory platelets as important contributors to AH pathology. Moreover, antiplatelet agents — or, more specifically, S100A9 targeted drugs — are potential therapeutic strategies in AH.
Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Adjuvant Therapy for Resected Adenocarcinoma of the Pancreas
Jethwa, Krishan R., Newman, Neil, Selfridge, J. Eva, Anker, Christopher J., Abood, G., Akselrod, Dmitriy, Attallah, Joseph, Hallemeier, Christopher L., Jin, Zhaohui, Kim, Ed, Kennedy, Timothy, Lee, Percy, Ling, Diane C., Miller, Eric D, Sharma, Navesh, Small, William, Tchelebi, Leila, Russo, Suzanne , Jethwa, Krishan R. , Newman, Neil B. , Anker, Christopher J. , Abood, Gerard, Akselrod, Dmitriy , Hallemeier, Christopher Leigh , Hassett, Leslie C. , Lee, Percy, Small, William , Tchelebi, Leila T.

Mayo Clinic

American Journal of Clinical Oncology | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/coc.0000000000001347 | PMID 42622289 Get It

Objectives: Rates of locoregional recurrence and distant metastases are high following curative-intent resection for patients with localized pancreatic adenocarcinoma. Adjuvant therapies have been investigated with the intent to reduce the risk of recurrence and improve OS. The objective of this study is to update and summarize the current evidence for adjuvant therapy following surgical resection for nonmetastatic PDAC with a focus on high-level evidence and randomized controlled trials is provided. Methods: This multispecialty-led committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and surgical oncology. Using the population, intervention, comparator, outcome, timing and study design framework, evidence regarding treatment outcomes was assessed using Cochrane and PRISMA methodology. Eligible studies included prospective and retrospective (n≥25) studies published between January 1, 2013 and February 13, 2026, from Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Database of Systematic Review, and Scopus databases. Study type and quality were assessed. Well-established RAND/UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options. Results: Of the 74 references used as evidence, 74 are categorized as therapeutic references. Study type and quality for the references were assessed, and included 31 well-designed studies (phase II randomized and phase III), 14 moderately well-designed studies that account for most common biases (matched cohort and phase II studies), 28 studies with design limitations (retrospective reviews), and 1 reference meta-analysis. Conclusions: This systematic review and guidelines provide up-to-date recommendations focusing on recent advancements for adjuvant treatment of resected PDAC using modern systemic therapy regimens and selective use of radiotherapy using modern techniques.
Cerebellar tonsillar ectopia: Navigating intracranial hypertension and hypotension in a pediatric patient
Lai, Sammie , Nguyen, Sarah, Pandya, Jay, Taskin, Didem, Hana, Leticia Schafer Abu, Shah, Chetan, Kim, J H , Nguyen, Sarah, Shah, Chetan

Mayo Clinic

Cephalalgia Reports | August 18, 2026 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/25158163261478626 Get It

Background Cerebellar tonsillar ectopia may arise from altered cerebrospinal fluid (CSF) dynamics and can mimic Chiari I malformation. Differentiating between pressure-induced tonsillar descent and congenital malformations is essential. We present an interesting case that visualizes variable tonsillar displacement levels as an indicator of CSF dynamics. Case A 3-year-old boy presented with headache and sixth nerve palsy and was diagnosed with idiopathic intracranial hypertension. Initial magnetic resonance imaging (MRI) revealed a 5 mm descent of the cerebellar tonsils. During hospitalization, the patient underwent mastoidectomy for an incidental T2 hyperintense lesion. Subsequent MRI scans demonstrated the resolution of tonsillar displacement. At age 5, the patient experienced worsening headache. Brain MRI revealed a 13 mm descent of the cerebellar tonsils below the foramen magnum and pachymeningeal enhancement. Further evaluation revealed transtemporal CSF leakage through the previous mastoidectomy site into the soft neck tissues. Conclusion This case exemplifies cerebellar tonsillar displacement associated with both intracranial hypertension (push) and hypotension (pull), illustrating opposite causal directions of CSF dynamics in the same patient. Understanding the phenomenon as a result of dynamic CSF balance rather than unidirectional force or fixed pathophysiology can enhance monitoring of patients.
Neighbourhood Deprivation Is Associated With Greater Mortality in Patients With Alcohol‐Associated Liver Disease
Ghani, Leith , Faulkner, Claire , Aboona, Majd B. , Hariharan, Pradhan , Rangan, Pooja , Altaf, Amal, Garcia, David O., Kim, Donghee , Noureddin, Mazen, Kardashian, Ani , Fallon, Michael B. , Faulkner, Claire S , Chen, V L , Kim, Donghee , Arab, Juan P , Díaz, Luis A , Kardashian, Ani , Fallon, Michael B , Wijarnpreecha, Karn , Ghani, Leith K. , Chen, Vincent , Arab, Juan Pablo , Noureddin, Mazen , Díaz, Luis Antonio , Wijarnpreecha, Karn

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/apt.70930 | PMID 42608666 Get It

ABSTRACT Background and Aim Significant health disparities persist in alcohol‐associated liver disease (ALD), largely driven by social determinants of health (SDOH). However, the influence of neighbourhood‐level SDOH on ALD outcomes remains underexplored. In this study, we aimed to evaluate how neighbourhood‐level SDOH are associated with disease burden, comorbid conditions, and mortality in individuals with ALD. Methods We conducted a retrospective cohort study of patients with ALD in the Banner Health System, representing hospitals across Arizona, California, Nevada, Wyoming and Colorado, from January 2012 to October 2024 using ICD codes. Neighbourhood‐level SDOH were quantified using the Social Deprivation Index (SDI). Patients were stratified into quartiles based on SDI score, with Quartile 4 representing the most socioeconomically disadvantaged neighbourhoods. Primary outcomes included incidence of mortality, cirrhosis, major adverse liver outcome (MALO), Type 2 diabetes mellitus, any cancer, and major adverse cardiovascular events (MACE). A multivariable competing risk analysis was performed adjusting for age, sex, race/ethnicity, insurance type, primary language, smoking status, Type 2 diabetes mellitus, hypertension, hyperlipidemia, aspirin use, statin use, alcohol use disorder and a composite mental‐health/substance‐use disorder variable encompassing depression, anxiety disorders, post‐traumatic stress disorder, bipolar disorder, schizophrenia, and non‐alcohol substance use disorders. Results Among 11,394 patients with ALD and available SDI data, 6747 had ≥ 365 days of follow‐up. The average age was 51 years and 65.6% were female; 68.8% were non‐Hispanic White, 19.7% Hispanic, 5.9% Native American/Alaskan Native (NA), 3.2% Black, and 0.4% Asian/Pacific Islanders. Patients residing in the most disadvantaged neighbourhoods (Quartile 4) were significantly younger, more likely to be female, had a higher median BMI, and more frequently reported a non‐English primary language compared with those in the least disadvantaged areas (Quartile 1). Patients in the most deprived neighbourhoods were more likely to be Hispanic, Black, or Native American/Alaska Native and to be uninsured or on Medicaid, whereas those in the least disadvantaged neighbourhoods predominantly had private insurance. Individuals in Quartile 4 had increased mortality (adjusted hazard ratio [aHR]: 1.48, 95% Confidence Interval [CI]: 1.09–2.01) compared with individuals in Quartile 1. Conclusions In this large and demographically diverse ALD cohort, residing in socioeconomically disadvantaged neighbourhoods was associated with increased risk of mortality. These findings support the need for contextually tailored clinical interventions and broader treatment strategies that target upstream sociocultural and environmental factors that are associated with health outcomes. Addressing neighbourhood‐level SDOH through community engagement, policy reform, and cross‐sector partnerships to improve collaborative care efforts is needed to reduce health disparities in ALD.
Characterization of Ventilator-Associated Pneumonia in Patients Receiving Extracorporeal Membrane Oxygenation Support
Kim, Myeongji , Lynn-Green, Erika E , Igwilo-Alaneme, Rita I., Marcus, Joseph E , Lyster, Haifa, Seelhammer, Troy G. , Riera, Jordi, Shah, Aditya, Bohman, John Kyle, Marcus, Joseph , Ranganath, Nischal , Wieruszewski, Patrick M. , Lynn-Green, Erika , Igwilo-Alaneme, Rita , Lyster, Haifa S. , Bohman, J. Kyle , Riera, Jordi

Mayo Clinic

ASAIO Journal | August 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mat.0000000000002820 | PMID 42606818 Get It

In this retrospective cohort study at a quaternary referral hospital, 829 adult patients supported by extracorporeal membrane oxygenation (ECMO) between January 1, 2014, and October 31, 2024, were screened for ventilator-associated pneumonia (VAP). The incidence of VAP in ECMO-supported patients was 17.7 per 1,000 ECMO days (venoarterial [VA] ECMO, 22.1 per 1,000 ECMO days; venovenous [VV] ECMO, 13.8 per 1,000 ECMO days). Median time from ECMO cannulation to diagnosis of VAP was 4 (interquartile range [IQR], 3–8; range 1–84) days. Gram-negative bacteria comprised most respiratory pathogens. A significant increase in minimum ECMO sweep was noted from 2 days before to 1 day after VAP diagnosis (0.79 L/min increase, p = 0.004). Only 38 of 153 patients (24.8%) met National Healthcare Safety Network (NHSN) VAP definitions. After creating a modified VAP definition, which included an ECMO sweep increase of 0.5 L/min as evidence of worsening respiratory status, 78 (51.0%) met the modified definition. Those who met the modified VAP definition had worse in-hospital (60.3% vs. 28.0%, p < 0.001), 30 day (33.3% vs. 17.3%, p = 0.023), and 90 day (53.8% vs. 25.3%, p < 0.001) mortality compared with those who did not meet the modified VAP definition. The incorporation of ECMO parameters into diagnostic criteria may improve detection sensitivity, but further validation is necessary before implementation.
Pharmacoexposomics: The Environmental Complement to Pharmacogenomics to Advance Precision Medicine
Reho, Paolo, Athreya, Arjun P. , Hripcsak, George, Kim, Soon-Mi, Li, Shuzhao, Walker, Douglas I., Patel, Chirag J., Miller, Gary W., Reho, Paolo , Thaker, Vidhu , Cremers, Serge , Go, Young‐Mi , Hripcsak, George , Hu, Xin , Jones, Dean P. , Lazaridis, Konstantinos N. , Li, Shuzhao, Pennell, Kurt D. , Singh, Randolph R. , Walker, Douglas Ian , Patel, Chirag J.

Mayo Clinic

Annual Review of Pharmacology and Toxicology | August 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1146/annurev-pharmtox-062624-113658 | PMID 42594291 Get It

Despite advances in pharmacogenomics that have led to innovative therapeutic strategies, substantial interindividual variability in drug efficacy and toxicity persists. Both endogenous and exogenous factors contribute to this unexplained variation, resulting in suboptimal treatment effectiveness, unnecessary healthcare costs, preventable mortality, and significant human suffering. The emerging field of exposomics is aimed at addressing the complex exposures that impact human health and offers an opportunity to interrogate how these exposures influence drug actions and outcomes. Here, we introduce pharmacoexposomics as a complementary framework that systematically quantifies the body's metabolic response to drug and environmental exposures using high-resolution mass spectrometry. We then present IndiPHARM (Individualized Pharmacology), a multi-institution, Advanced Research Projects Agency for Health–supported platform designed to integrate population-scale pharmacoexposomics with pharmacogenomics and clinical data to elucidate interindividual variability in drug response, identify adverse reactions, and inform tailored, effective treatment strategies that advance precision medicine.
Leveraging large language models to enhance cytopathology: Opportunities, challenges, and future directions; a practical review from the ASC Clinical Practice Committee
Bilal, K. Hasan, Gibson, Joanna, LEVI, ANGELIQUE W. , Oen, Handy, Robila, Valentina , Saieg, Mauro , Shi, Qiuying , Torous, Vanda F. , Zeynettin, Akkus, Zhao, Melissa , Lin, Oscar , Robila, Valentina , Saieg, Mauro T , Torous, Vanda F , Lin, Oscar , Gibson, Joanna , Kim, David , Nassar, Aziza , Oen, Handy O., Akkus, Zeynettin

Mayo Clinic

Cancer Cytopathology | August 12, 2026 | Volume: 134 | Issue: 9 | Pages: No page available

10.1002/cncy.70134 | PMID 42585107 Get It

Abstract Large language models (LLMs) and vision‐language models represent a fundamentally different category of artificial intelligence (AI) compared to prior image analysis approaches in digital pathology, which have largely been based on convolutional neural network architectures. This review from the American Society of Cytopathology Clinical Practice Committee examines the current evidence for LLM and vision‐language model applications in cytopathology, including structured reporting, diagnostic assistance, quality control, education, and workflow integration. The distinction between applications with preliminary evidence and those that remain hypothetical is described. A detailed assessment of the challenges that must be addressed before clinical deployment, including hallucination risk, limited explainability, bias, data privacy, validation gaps, and infrastructure barriers is discussed. A review of the regulatory landscape in the United States and European Union as it applies to AI‐enabled software as a medical device is provided. Recommendations addressing cytopathology‐specific benchmarks, multi‐institutional validation, transparent governance, and incremental deployment beginning with low‐risk applications are suggested. In the current environment, LLMs have the potential to augment cytopathology practice, but responsible adoption requires rigorous validation and sustained collaboration among cytopathologists, AI researchers, and regulatory bodies.
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ ‐1 Study Eligibility: A Large Global Analysis in a Real‐World Setting
Prinzi, Federica Lo , Rimini, Margherita , Ikeda, Masafumi, Antonuzzo, Lorenzo, Kim, Jin Won, Pressiani, Tiziana, Peeters, Frederik , Pinato, David J., Pircher, Chiara, Tamberi, Stefano, Couto, Nuno, Chon, Hong Jae, Martirena, A. , Lamarca, Angela, Perkhofer, Lukas , Kim, Il Hwan, Pinto, C. , Kang, Beodeul, Pastorino, Alessandro , Changhoon, Yoo, Rodriquenz, Maria Grazia , Scartozzi, Mario, Zumstein, Lucrezia , Ghidini, Michele, Aprile, Giuseppe , Spinelli, Gian Paolo , Yung‐Yeh, Su, Warmington, Emily , Lancianese, Alessia , Satake, Tomoyuki, Bekaii‐Saab, Tanios, Lavacchi, Daniele, Passeri, Laura , Kang, Minsu, Prete, Alessandra Anna, Bozzarelli, Silvia, Persano, Mara , Masi, Gianluca, Balsano, Rita , Lonardi, Sara, Salani, Francesca, Camera, Silvia, Vogel, Arndt, Rimassa, Lorenza, Rimassa, Lorenza , Vivaldi, Caterina , Farinea, Giovanni , Prager, Gerald W , Chan, Stephen L , Niger, Monica , Fornaro, Lorenzo , Casadei-Gardini, Andrea , Lo Prinzi, Federica , Rimassa, Lorenza , Saborowski, Anna , Rimini, Margherita , Ikeda, Masafumi , Abidoye, Oluseyi , Lucchetti, Jessica , Antonuzzo, Lorenzo , Kim, Jin Won , Nichetti, Federico , Pressiani, Tiziana , Vivaldi, Caterina , Rapposelli, Ilario Giovanni , Braconi, Chiara , Pinato, David J. , Tamburini, Emiliano , Pircher, Chiara , Tamberi, Stefano , Castet, Florian , Verrico, Monica , Parisi, Alessandro , Couto, Nuno, Chon, Hong Jae , Lamarca, Angela , Landriscina, Matteo , Finkelmeier, Fabian , Oneda, Ester , Avallone, Antonio , Dell’Aquila, Emanuela , Kim, Il Hwan, Formica, Vincenzo , Garajova, Ingrid , Kang, Beodeul , Corallo, Salvatore , Fenocchio, Elisabetta , Diana, Anna , Schirripa, Marta , Scartozzi, Mario , Ghidini, Michele , Prager, Gerald W. , Chan, Stephen L. , Warmington, Emily, Satake, Tomoyuki , Bekaii‐Saab, Tanios , Giordano, Guido , Ferrara, Michele , Kang, Minsu, Prete, Alessandra Anna , Bozzarelli, Silvia , Masi, Gianluca , Niger, Monica , Lonardi, Sara , Salani, Francesca , Camera, Silvia , Vogel, Arndt , Fornaro, Lorenzo , Casadei‐Gardini, Andrea

Mayo Clinic

International Journal of Cancer | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ijc.70699 | PMID 42581755 Get It

ABSTRACT Many real‐world patients with advanced biliary tract cancer (BTC) are excluded by TOPAZ‐1 criteria; this study assessed cisplatin and gemcitabine plus durvalumab (CGD) efficacy and safety in these patients. Data from 1358 patients with advanced BTC treated with first‐line CGD across 55 international centers were retrospectively analyzed. Patients were classified as TOPAZ‐1‐in (meeting all inclusion criteria) or TOPAZ‐1‐out (meeting ≥ 1 exclusion criterion). Primary endpoints were overall survival (OS) and progression‐free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and safety. Furthermore, OS and PFS of the TOPAZ‐1‐out cohort were compared with reconstructed survival data from the phase III trial. 912 (67.1%) patients were classified as TOPAZ‐1‐in , and 446 (32.9%) as TOPAZ‐1‐out . After a median follow‐up of 14.5 months (95% CI: 13.7–36.5), OS was 16.1 months in TOPAZ‐1‐in and 12.5 months in TOPAZ‐1‐out (HR 0.69, 95% CI: 14.6–16.5, p = 0.0001); PFS was 8.2 versus 6.5 months (HR 0.73, 95% CI: 7.1–8.1, p < 0.0001). Median OS in the TOPAZ‐1‐out cohort (12.5 months) was nearly identical to the phase III trial experimental arm (12.9 months; HR 1.15, p = 0.13); for PFS the HR was 1.12 (95% CI 0.93–1.42; p = 0.09). Among TOPAZ‐1‐out patients, active infection, elevated bilirubin, and ECOG PS > 1 were linked to poorer OS, while no detrimental impact emerged for ALT/AST abnormalities, corticosteroid use, renal or hematologic parameters, or prior surgery within 6 months, suggesting treatment effectiveness was broadly maintained across clinical subgroups. Furthermore, TOPAZ‐1‐out patients experienced no significant increase in adverse events compared with the TOPAZ‐1‐in group. Real‐world data suggest CGD may be effective in TOPAZ‐1‐out patients, with no evident increase in toxicity, supporting the potential expanded use of the regimen in clinical practice.
Liver Point-of-Care Ultrasound (POCUS): Roadmap for training, credentialing, and implementation
Debes, Jose D., Gougol, Amir , Kim, W. Ray, Debes, José D. , Kono, Yuko , Dolinger, Michael Todd

Mayo Clinic

Hepatology Communications | August 11, 2026 | Volume: 10 | Issue: 9 | Pages: No page available

10.1097/hc9.0000000000001016 | PMID 42579772 Get It

Point-of-care ultrasound (POCUS) offers unique, real-time advantages for assessing liver disease, benefiting both health care providers and patients. It has been shown to enhance patient care and satisfaction across a variety of medical specialties. Although liver POCUS is practiced widely in many parts of the world, its use in the United States remains limited. Liver POCUS enables rapid assessment of specific hepatic conditions, including both vascular and parenchymal abnormalities, and can play a key role in timely management decision-making—such as guiding the use of diuretics or volume expanders. Once liver POCUS is established, ultrasonography-enabled procedures, such as procedure guidance and shear wave elastography, may be adopted and enrich the practice of hepatology in the future. This paper serves as a summary of the American Association for the Study of Liver Diseases' (AASLD) current position on liver POCUS, offering proposed imaging protocols, recommendations for training and credentialing, and practical guidelines for implementation in clinical settings.
Age-Specific Efficacy of Platelet-Rich Plasma in Tonsillectomy: A Systematic Review and Meta-Analysis
Kim, Ji‐Sun , Stybayeva, Gulnaz , Hwang, Se Hwan , Stybayeya, Gulnaz , Hwang, Se Hwan , Kim, Ji-Sun

Mayo Clinic

Journal of Clinical Medicine | August 10, 2026 | Volume: 15 | Issue: 16 | Pages: 6182

10.3390/jcm15166182 | PMID 42652586 Get It

Background/Objectives: The objective of this study was to evaluate age-specific effects of intraoperative platelet-rich plasma (PRP) administration on postoperative pain, wound healing, and bleeding after tonsillectomy. Methods: PubMed, Embase, Scopus, Google Scholar, and Cochrane databases were searched from inception to October 2025. Randomized controlled trials comparing intraoperative PRP with placebo or no treatment in patients undergoing tonsillectomy were included. Data on postoperative pain, wound healing, and bleeding were extracted and analyzed using standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs). Subgroup analyses were performed by age (adults versus children) and by postoperative day. Results: Nine randomized controlled trials comprising 442 participants were included. In adults, PRP significantly reduced postoperative pain (SMD = −1.26 [−1.70 to −0.81]) and improved wound healing (SMD = −1.43 [−2.65 to −0.22]). The analgesic effect was greatest during the early recovery period (postoperative days 0–5) and diminished thereafter. There were no significant differences in primary postoperative bleeding (OR = 0.49 [0.04 to 5.61]) or secondary postoperative bleeding (OR = 0.23 [0.02 to 2.16]) between the PRP and control groups. In children, PRP did not significantly affect pain or bleeding outcomes. Conclusions: Intraoperative PRP may reduce early postoperative pain and may promote mucosal recovery in adults. However, its clinical efficacy in children remains unclear. Further well-designed, age-stratified trials are warranted to clarify the role of PRP in enhancing postoperative recovery.